SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DewDiligence_on_SI who wrote (10202)9/9/2009 12:43:13 PM
From: Harold Engstrom  Read Replies (3) of 10345
 
Dew Diligence, my point was that risk clearly does NOT increase with time on drug. Seemingly, only the initial group of EU patients that were VERY sick are contracting PML in any real numbers. We should have seen more patients from the far more sizable group that adopted Tysabri in late 2007 and 2008 contract PML if time were a factor. We have not.

And the number of AERs prevented by using Tysabri instead of copaxone or interferons FAR outweighs the risks for patients with active MS (in my opinion.)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News